Skip to main content
. 2019 Oct 29;10(59):6323–6333. doi: 10.18632/oncotarget.27259

Figure 3. RXDX-105 induces neuroblastoma cell apoptosis and cell cycle arrest.

Figure 3

(A) Neuroblastoma cells were plated and treated with vehicle control or decreasing doses of RXDX-105 with additional caspase 3/7 reagent. Cells were monitored with continuous live cell imaging and total caspase cleavage was determined by counting sites of activated caspases (in green) at 72 hours. (B) Cell lysates were assessed for PARP cleavage by Western blot after 24 hours of RXDX-105 treatment. (C) The effect of RXDX-105 treatment on cell cycle was assessed using flow cytometry for DNA content after 24 hours of treatment.